Skip to main content
SpringerLink
Log in

Verteporfin worth it for age-related macular degeneration in the UK?

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Rights and permissions

Reprints and permissions

About this article

Cite this article

Verteporfin worth it for age-related macular degeneration in the UK?. Pharmacoecon. Outcomes News 370, 5 (2002). https://doi.org/10.1007/BF03279283

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03279283

Keywords

Search

Navigation